Holen Sie sich die Stockscreener-App
6.11
0.65%
-0.04
Handel nachbörslich:
6.11
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - simplywall.st
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge - Investing.com Nigeria
YCANTH (VP-102): FDA-Approved Treatment for Molluscum Contagiosum and Dermatology Pipeline Overview | 2025 10-K Highlights - Minichart
VRCA: Revenue surged 368% in 2025, with strong YCANTH growth, cost cuts, and pipeline advances - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Verrica (VRCA) Achieves Strong Financial Milestones in 2025 - GuruFocus
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand - TradingView
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - Yahoo Finance
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold - MarketBeat
Earnings Outlook For Verrica Pharmaceuticals - Benzinga
FRAUD AND MANIPULATION—E.D. Pa.: Class certified in action against pharma company for allegedly misleading investors - VitalLaw.com
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results - MyChesCo
Verrica Secures $10 Million Milestone as YCANTH Wins Approval in Japan - MSN
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISI - GuruFocus
Is Verrica Pharmaceuticals Inc stock good for income investorsPortfolio Gains Summary & Safe Capital Growth Tips - baoquankhu1.vn
Aug Highlights: Can Verrica Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Verrica Pharmaceuticals Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Verrica Investors Gain Class Status Over Delayed FDA Approval - Bloomberg Law News
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 - Sahm
Pharma Co. Investors Secure Class Cert. Over FDA Obstacles - Law360
Verrica Pharmaceuticals to Report Fourth Quarter and Full - GlobeNewswire
Verrica schedules March 11 call on 2025 results and skin drug business - Stock Titan
Verrica Pharmaceuticals (VRCA) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Verrica Pharmaceuticals at TD Cowen Conference: Strategic Insights By Investing.com - Investing.com Canada
VRCA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VRCA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Common Warts Market: Expanding Revenue Landscape to 2034 – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Common Warts Market: Expanding Revenue Landscape To 2034 Delveinsight Nielsen Biosciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Mena FN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Fed Impact: How does Verrica Pharmaceuticals Inc score in quality rankingsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - Yahoo Finance
Watch Verrica's CEO speak live from TD Cowen's Boston healthcare conference - Stock Titan
How does Verrica Pharmaceuticals Inc. perform in inflationary periodsExit Point & Smart Allocation Stock Tips - mfd.ru
Verrica Pharmaceuticals: Strategic Execution Takes Center Stage - AD HOC NEWS
West Chester-Based Verrica Partner Launches YCANTH in Japan - MyChesCo
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer - MyChesCo
Verrica Pharmaceuticals Launches YCANTH in Japan with Torii Pharmaceutical - Intellectia AI
Verrica Pharma appoints Chris Chapman as CCO - The Pharma Letter
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - marketscreener.com
What’s the outlook for Verrica Pharmaceuticals Inc.’s sector2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer - marketscreener.com
Verrica Pharmaceuticals (VRCA) Appoints New Chief Commercial Off - GuruFocus
Verrica Pharmaceuticals Appoints Chris Chapman As Chief Commercial Officer - TradingView
Verrica’s Japanese Market Debut: A Strategic Expansion Unfolds - AD HOC NEWS
Verrica’s partner launches molluscum treatment in Japan By Investing.com - Investing.com Australia
Verrica’s partner launches molluscum treatment in Japan - Investing.com Nigeria
Verrica announces launch of Ycanth in Japan by Torii - The Pharma Letter
Verrica Pharmaceuticals Announces Launch Of Ycanth® For The Treatment Of Molluscum Contagiosum In Japan - TradingView
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan - Investing.com Nigeria
Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical - The Manila Times
Verrica Pharmaceuticals Announces Launch of YCANTH® for the - GlobeNewswire
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):